Dr Stephen Rankin
- Clinical Research Fellow (Cardiovascular & Metabolic Health)
Publications
2023
Elyan, B. M.P., Rankin, S., Jones, R. , Lang, N. N. , Mark, P. B. and Lees, J. S. (2023) Kidney disease patient representation in trials of combination therapy with VEGF-signaling pathway inhibitors and immune checkpoint inhibitors: a systematic review. Kidney Medicine, 5(7), 100672. (doi: 10.1016/j.xkme.2023.100672) (PMID:37492115) (PMCID:PMC10363559)
Henriksen, P. A., Rankin, S. and Lang, N. N. (2023) Cardioprotection in patients at high risk of anthracycline-induced cardiotoxicity: JACC: CardioOncology Primer. JACC: CardioOncology, 5(3), pp. 292-297. (doi: 10.1016/j.jaccao.2023.05.004) (PMID:37397086) (PMCID:PMC10308056)
2022
Rankin, S., McGuire, J., Chekroud, M., Alakandy, L. and Mukhopadhyay, B. (2022) Evaluating xanthochromia in the diagnosis of subarachnoid haemorrhage in Scotland in the Era of modern computed tomography. Scottish Medical Journal, 67(2), pp. 71-77. (doi: 10.1177/00369330211072264) (PMID:35105220)
2017
Rankin, A. J. and Rankin, S. H. (2017) Cardioverting acute atrial fibrillation and the risk of thromboembolism: not all patients are created equal. Clinical Medicine, 17(5), pp. 419-423. (doi: 10.7861/clinmedicine.17-5-419) (PMID:28974590)
Rankin, S., Elder, D.H., Ogston, S., George, J., Lang, C.C. and Choy, A.M. (2017) Population-level incidence and monitoring of adverse drug reactions with long-term amiodarone therapy. Cardiovascular Therapeutics, 35(3), e12258. (doi: 10.1111/1755-5922.12258) (PMID:28276175)
Ben Batalla, I. et al. (2017) Axl blockade by BGB324 inhibits BCR-ABL tyrosine kinase inhibitor-sensitive and -resistant chronic myeloid leukemia. Clinical Cancer Research, 23(9), pp. 2289-2300. (doi: 10.1158/1078-0432.CCR-16-1930) (PMID:27856601)
2015
Rankin, A. J. , Rankin, S. H. and Rankin, A. C. (2015) Auscultating heart and breath sounds through patients’ gowns: who does this and does it matter? Postgraduate Medical Journal, 91(1077), pp. 379-383. (doi: 10.1136/postgradmedj-2015-133321) (PMID:26183342)
Articles
Elyan, B. M.P., Rankin, S., Jones, R. , Lang, N. N. , Mark, P. B. and Lees, J. S. (2023) Kidney disease patient representation in trials of combination therapy with VEGF-signaling pathway inhibitors and immune checkpoint inhibitors: a systematic review. Kidney Medicine, 5(7), 100672. (doi: 10.1016/j.xkme.2023.100672) (PMID:37492115) (PMCID:PMC10363559)
Henriksen, P. A., Rankin, S. and Lang, N. N. (2023) Cardioprotection in patients at high risk of anthracycline-induced cardiotoxicity: JACC: CardioOncology Primer. JACC: CardioOncology, 5(3), pp. 292-297. (doi: 10.1016/j.jaccao.2023.05.004) (PMID:37397086) (PMCID:PMC10308056)
Rankin, S., McGuire, J., Chekroud, M., Alakandy, L. and Mukhopadhyay, B. (2022) Evaluating xanthochromia in the diagnosis of subarachnoid haemorrhage in Scotland in the Era of modern computed tomography. Scottish Medical Journal, 67(2), pp. 71-77. (doi: 10.1177/00369330211072264) (PMID:35105220)
Rankin, A. J. and Rankin, S. H. (2017) Cardioverting acute atrial fibrillation and the risk of thromboembolism: not all patients are created equal. Clinical Medicine, 17(5), pp. 419-423. (doi: 10.7861/clinmedicine.17-5-419) (PMID:28974590)
Rankin, S., Elder, D.H., Ogston, S., George, J., Lang, C.C. and Choy, A.M. (2017) Population-level incidence and monitoring of adverse drug reactions with long-term amiodarone therapy. Cardiovascular Therapeutics, 35(3), e12258. (doi: 10.1111/1755-5922.12258) (PMID:28276175)
Ben Batalla, I. et al. (2017) Axl blockade by BGB324 inhibits BCR-ABL tyrosine kinase inhibitor-sensitive and -resistant chronic myeloid leukemia. Clinical Cancer Research, 23(9), pp. 2289-2300. (doi: 10.1158/1078-0432.CCR-16-1930) (PMID:27856601)
Rankin, A. J. , Rankin, S. H. and Rankin, A. C. (2015) Auscultating heart and breath sounds through patients’ gowns: who does this and does it matter? Postgraduate Medical Journal, 91(1077), pp. 379-383. (doi: 10.1136/postgradmedj-2015-133321) (PMID:26183342)